Monoclonal Antibody Development Targeting IL-17 for Autoimmune Diseases

Monoclonal antibody (mAb) targeting interleukin (IL)-17 has been paid increasing attention by researchers and clinicians in the field of autoimmune diseases. Equipped with world-leading technology platforms and professional scientific experts, Creative Biolabs has accumulated rich experience in custom inflammatory cytokine antibody development. Our scientists are dedicated to offering first-class anti-IL-17 antibody development services with the best quality and in a time-saving manner.

IL-17 and Autoimmune Diseases

IL-17 was initially termed as cytotoxic T lymphocyte-associated antigen-8 (CTLA-8), isolated from a rat-mouse T cell hybridoma in 1993. Subsequently, IL-17 was also identified in humans. The IL-17 family consists of 6 proteins that share homology among them, and are known as IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Among them, IL-17A and IL-17F are known for their important functional and biological properties. They are 50% homologous in the amino acid sequence. They exist either as homodimers or IL-17A/F heterodimers. IL-17A is known to be secreted by many cell types including CD4+ (Th17), CD8+ (Tc17), γδ+ T cells, natural killer cells, mast cells, neutrophils among other cell types. In healthy conditions, the levels of IL-17A in human sera are undetectable, however, the levels are distinctly increased in inflammatory bowel disease, psoriasis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Although IL-17 is known to have protective effects in infections, increased IL-17 has been shown to promote inflammation in autoimmune diseases by mobilizing, recruiting, and activating different cells.

Fig.1 IL-17A in the pathogenesis of psoriasis. (Brembilla, 2018)

Antibodies Targeting IL-17 for the Treatment of Autoimmune Diseases

Regulating IL-17 levels by using IL-17A-blocking antibodies has been shown to attenuate autoimmune diseases. Several clinical trials of anti-IL-17 mAbs are underway to treat psoriasis. Studies have shown promising results in targeting IL-17 signaling pathways in the treatment of autoimmune diseases.

mAb Targeting IL-17 Development at Creative Biolabs

Given the role of IL-17 in autoimmune diseases, targeting IL-17/IL-17 receptor (IL-17R), IL-17-producing pathways, or IL-17-mediated signaling pathways can be considered for future therapy in autoimmune diseases. IL-17 blocking antibodies may represent a promising approach for the treatment of this disease. Professional technical scientists, extensive experience, and comprehensive powerful platforms make Creative Biolabs a perfect partner to assist our clients' specific needs in anti-IL-17 antibody development. We would like to share our knowledge and passion for anti-IL-17 antibody development to facilitate our customers' research and project development.

Highlights of Monoclonal Antibody Development Targeting IL-17

• Comprehensive powerful platforms, including antigen-specific B lymphocytes sorting platform, hybridoma platform and phage display platform
• Diverse species, as requested
• Comprehensive validation, including enzyme-linked immunosorbent assay (ELISA), western blot (WB), surface plasmon resonance (SPR), and Bio-layer interferometry (BLI).
• Best after-sale service

Creative Biolabs is proud to offer the most comprehensive services in anti-IL-17 antibody development to facilitate our customers' research and project development. Through our high-throughput platforms, clients could accelerate their research by reducing project costs and timelines.

References

1. Brembilla, N.C.; et al. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Frontiers in immunology. 2018, 9:1682.
2. SAKKAS, L.I.; et al. New treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Frontiers in pharmacology. 2019, 10:872.

For Research Use Only | Not For Clinical Use